dc.contributor.author | O'FARRELLY, CLIONA | en |
dc.contributor.author | LYNCH, LYDIA | en |
dc.date.accessioned | 2015-12-09T11:45:56Z | |
dc.date.available | 2015-12-09T11:45:56Z | |
dc.date.issued | 2012 | en |
dc.date.submitted | 2012 | en |
dc.identifier.citation | Lynch L, Nowak M, Varghese B, Clark J, Hogan AE, Toxavidis V, Balk SP, O'Shea D, O'Farrelly C, Exley MA, Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production., Immunity, 37, 3, 2012, 574-87 | en |
dc.identifier.issn | 1074-7613 | en |
dc.identifier.other | Y | en |
dc.description | PUBLISHED | en |
dc.description.abstract | Invariant natural killer T (iNKT) cells are evolutionarily conserved innate T cells that influence inflammatory responses. We have shown that iNKT cells, previously thought to be rare in humans, were highly enriched in human and murine adipose tissue, and that as adipose tissue expanded in obesity, iNKT cells were depleted, correlating with proinflammatory macrophage infiltration. iNKT cell numbers were restored in mice and humans after weight loss. Mice lacking iNKT cells had enhanced weight gain, larger adipocytes, fatty livers, and insulin resistance on a high-fat diet. Adoptive transfer of iNKT cells into obese mice or in vivo activation of iNKT cells via their lipid ligand, alpha-galactocylceramide, decreased body fat, triglyceride levels, leptin, and fatty liver and improved insulin sensitivity through anti-inflammatory cytokine production by adipose-derived iNKT cells. This finding highlights the potential of iNKT cell-targeted therapies, previously proven to be safe in humans, in the management of obesity and its consequences | en |
dc.description.sponsorship | We are grateful to B. Kahn, O. Peroni, and the Metabolic Physiology Core, Boston for assistance with DEXA imaging and adipocyte measurement. We thank G. Hotamisligil of the Harvard School of Public Health and U. von Andrian of the Harvard Medical School for fruitful discussions, and M. Brenner for kind assistance and discussion of this manuscript. We gratefully acknowledge F. Scheuplein and S. Jordan for mouse care. We also thank the Beth Israel Deaconess Medical Center (BIDMC) Flow Cytometry Core, especially J. Tigges, and the BIDMC Histology Core, especially S. White and L.H. Ang. This study was supported by NIH R21 CA143748, NIH R01 DK066917, U19 AI066313 (M.A.E.), US DOD W81XWH-09-1-0156 (S.P.B.), the UNESCO L’Oreal Fellowship (L.L.), the European Commission Marie Curie Fellowship (L.L.), Science Foundation Ireland (C.O’F.), and the Health Research Board, Ireland (L.L., A.E.H., D.O.S.). S.P.B. and M.A.E. have consulting relationships with NKT Therapeutics. The other authors have no conflicting financial interests. | en |
dc.format.extent | 574-87 | en |
dc.relation.ispartofseries | Immunity | en |
dc.relation.ispartofseries | 37 | en |
dc.relation.ispartofseries | 3 | en |
dc.rights | Y | en |
dc.subject | Invariant natural killer T (iNKT) cells | en |
dc.subject.lcsh | Invariant natural killer T (iNKT) cells | en |
dc.title | Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. | en |
dc.type | Journal Article | en |
dc.type.supercollection | scholarly_publications | en |
dc.type.supercollection | refereed_publications | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/ofarrecl | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/lynchl3 | en |
dc.identifier.rssinternalid | 87041 | en |
dc.identifier.doi | http://dx.doi.org/10.1016/j.immuni.2012.06.016 | en |
dc.rights.ecaccessrights | openAccess | |
dc.subject.TCDTheme | Immunology, Inflammation & Infection | en |
dc.identifier.uri | http://hdl.handle.net/2262/75175 | |